 JERSEY, Channel Islands, Dec. 10, 2020 GLOBE NEWSWIRE -- Quotient Limited NASDAQ:QTNT, a commercial-stage diagnostics company the Company, today announced that it received a request from the U.S. Food and Drug Administration FDA for additional testing data regarding the 510k application for the Initial Serological Disease Screening Microarray SDS and MosaiQ instrument. The data the FDA has requested relates to specific individual performance characteristics of the assays on the microarray. In response to this request, the Company intends to re-submit its application, with the additional data requested by the FDA, in early 2021. Following that submission, the Company is targeting to receive the FDA 510k clearance in mid-2021. 